CN112481371A - Kit for detecting copy number variation of PLP1 gene - Google Patents

Kit for detecting copy number variation of PLP1 gene Download PDF

Info

Publication number
CN112481371A
CN112481371A CN202011453524.8A CN202011453524A CN112481371A CN 112481371 A CN112481371 A CN 112481371A CN 202011453524 A CN202011453524 A CN 202011453524A CN 112481371 A CN112481371 A CN 112481371A
Authority
CN
China
Prior art keywords
plp1
copy number
gene
kit
primer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011453524.8A
Other languages
Chinese (zh)
Inventor
余艳
周梅华
李慧源
葛虎
朱加琳
唐春燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changsha Jinyu Medical Laboratory Co Ltd
Original Assignee
Changsha Jinyu Medical Laboratory Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changsha Jinyu Medical Laboratory Co Ltd filed Critical Changsha Jinyu Medical Laboratory Co Ltd
Priority to CN202011453524.8A priority Critical patent/CN112481371A/en
Publication of CN112481371A publication Critical patent/CN112481371A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention discloses a kit for detecting copy number variation of PLP1 gene. The kit comprises the following primer pairs: Q-PLP 1-LF: GGTCACATACACCCTGTCAAC, Q-PLP 1-LR: ccagagcgagcaccttaacatcgc, Q-PLP 1-MF: CAAGGTTTCACCACTGTTCAAATC, Q-PLP 1-MR: ccatctctaattatcctgggaG, Q-PLP 1-RF: GGGATTTGAGGAGGGAGACC, Q-PLP 1-RR: ggacggcaaagttgtaagACgC are provided. The method is simple and quick, low in pre-experiment cost and suitable for small-batch detection and verification.

Description

Kit for detecting copy number variation of PLP1 gene
Technical Field
The invention belongs to the technical field of biomedical detection, and particularly relates to a kit for detecting copy number variation of a PLP1 gene.
Background
The occurrence of a pathogenic mutation in the PLP1 gene can cause Pelizaeus-Merzbacher disease and spastic paraplegia type 2, and both are usually inherited in an X chromosome-linked recessive manner. Pelizaeus-Merzbacher disease is a slowly progressing leukodystrophy disease, mostly occurring in the early neonatal or infant stage, accompanied by nystagmus and usually associated with hypotonia, hypokinesia, delayed language development, and dysarthria. Over time, hypotonia often develops into spasticity, which in turn affects walking and communication. Cerebellar symptoms (gait disorder, dyskinesia, intention tremor, dyscephalia, etc.) often appear in childhood, and some patients may have extrapyramidal movement disorder, hearing loss and optic atrophy. About 30-40% of patients with diseases related to PLP1 gene variation have mutation in sequencing of human PLP1 gene, and 60-70% of human PLP1 gene have deletion/duplication.
Copy Number Variation (CNV) generally refers to an increase or decrease in Copy number of large genomic fragments of 1kb or more in length, mainly expressed as deletions, duplications, and inversions at the sub-microscopic level. Compared to SNPs, CNVs are not abundant but involve more genomic sequences with higher mutation rates. CNV is an important cause of human genetic diversity and genetic variation among individuals, and can be one of genetic polymorphisms in addition to a part of diseases. In 2004, two milestone studies found that this submicron variation in DNA copy number (<500kb) was widely present in the normal human genome.
CNV is an important component of genome variation (SV), and in the past years, with the continuous mining of genome information and the progress of detection technology, the CNV plays an increasingly important role in the pathogenesis of genetic diseases, and its pathogenic mechanism may be related to gene dose effect, gene disruption, gene fusion, location effect, etc. The deep research on the CNV can be helpful for better understanding the pathogenesis of genetic diseases and is beneficial to the research and development of molecular diagnosis and therapeutic means.
The most widely used method based on PCR technology is qPCR, which utilizes a relative quantitative real-time PCR system to analyze the copy number of a target gene (with copy number polymorphism) and a reference gene (without copy number polymorphism) of a detection sample by using a 2^ -delta Ct relative quantitative analysis method (Livak and Schmittgen, 2001). The method is simple and easy to operate, high in sensitivity, good in repeatability, high in speed and less in pollution, but is not suitable for high-throughput detection of large samples.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provides a kit for detecting copy number variation of PLP1 gene.
In order to achieve the purpose, the technical scheme provided by the invention is as follows:
the kit for detecting copy number variation of PLP1 gene contains the following primer pairs:
Q-PLP1-LF：GGTCACATACACCCTGTCAAC(SEQ ID NO.1)
Q-PLP1-LR：CCAGAGCGAGCACCTTAACATCGC(SEQ ID NO.2)
Q-PLP1-MF：CAAGGTTTCACCACTGTTCAAATC(SEQ ID NO.3)
Q-PLP1-MR：CCATCTCTAATTATCCTGGGAG(SEQ ID NO.4)
Q-PLP1-RF：GGGATTTGAGGAGGGAGACC(SEQ ID NO.5)
Q-PLP1-RR：GGACGGCAAAGTTGTAAGACGC(SEQ ID NO.6)。
preferably, the kit further comprises an internal reference primer pair:
Q-RP-F：GCAGATTTGGACCTGCGACGGG(SEQ ID NO.7)
Q-RP-R：GTGAGCGGCTGTCTCCACAACACC(SEQ ID NO.8)。
the procedure for amplification using the primer pairs in the above kit was as follows:
①：95℃，5min；
②：95℃，10s；55℃，30s；40Cycles；
③：95℃，15s；55℃，60s；95℃，15s。
the fluorescent chemistry used for qPCR can be divided into TaqMan fluorescent probes and SYBR Green fluorescent dyes. In the invention, the specific principle of copy number detection by using the SYBR Green fluorescent dye method is as follows: when the target sequence is a normal (copy number 2) sequence, the expression levels of the target sequence and the reference sequence are consistent, and the amplification efficiencies of the target sequence and the reference sequence are consistent by primer optimization in a preliminary experiment, C t values of the target sequence and C t values of the reference sequence are equal, and the target sequence amplification curve and the reference sequence amplification curve are matched together as shown on the amplification curve. The Normalized Ratio (NR) calculated according to the formula 2-delta Ct is about 1. When the target sequence has single copy deletion (copy number is 1), the expression level is equal to 1/2 of the internal reference gene RP, the C t value is increased by about 1, and the NR value calculated by a 2^ delta Ct formula after the amplification curve of the internal reference gene RP of the target gene amplification curve is about 0.5. When the double copy is deleted (the copy number is 0), the target gene does not exist, the amplification curve is similar to that of the negative control, and the NR value calculated according to the formula of 2-delta Ct is about 0. When the copy number of the target gene is increased (copy number >2), the expression level of the target gene relative to the reference gene RP is increased, the C t value is decreased, and the amplification curve of the target gene is further apart from the amplification curve of the reference gene RP as the amplification curve of the target gene is ahead of the amplification curve of the reference gene RP and the copy number of the target gene is increased. When the single copy is increased (the copy number is 3), the NR value calculated by the formula of 2^ -delta Ct is about 1.5; when the double copy increases (copy number is 4), the NR value calculated by the formula 2^ - Δ Δ Ct is around 2.0, the copy numbers of other cases are repeated, and so on.
The amplification length of the primer is generally about 100bp, and the primer is not suitable to be too long or too short; the designed primer should avoid hairpin structure and Single Nucleotide Polymorphism (SNP) site at the annealing position; the formation of dimer between primers is avoided, and the amplification efficiency of the primers is preferably close to 100%. In the invention, a PLP1 gene sequence exon (chrX:103,776,996-103,790, 598; hg38) is obtained through a UCSC database, a homologous sequence or a pseudogene region existing in a region to be detected is confirmed by using Blat in tools in the UCSC, a selected primer sequence avoids the homologous region, the annealing temperature is confirmed, whether a secondary structure exists or not is confirmed, and the secondary structure is reduced by changing one to two bases at the position of a 5' end of the primer, such as a Q-PLP1-MR primer, which comprises the following steps: ccatctctaattatcctgg (SEQ ID NO.9) was changed to ccatctctaattatcctgggaG (SEQ ID NO. 4). Finally, 3 groups of short fragment primer pairs (L/M/R) are designed, and a pair of internal reference primers RP (RPP30) is added, so that the specificity is strong, and the detection is accurate.
The invention detects copy number variation on PLP1 gene by QPCR method and Syber Green fluorescent dye method (chromosome absolute position: chrX 103,776,996-103,790, 598; hg 38). Compared with the problems of high cost, insufficient accuracy of copy number change detection results and the like of second-generation sequencing, the method is simple and quick, low in pre-experiment cost and suitable for small-batch detection and verification.
Drawings
FIG. 1: the amplification efficiency before optimization of Q-PLP1-LF + Q-PLP 1-LR;
FIG. 2: Q-PLP1-MF + Q-PLP1-MR optimized pre-amplification efficiency;
FIG. 3: amplification efficiency before optimization of Q-PLP1-RF + Q-PLP 1-RR;
FIG. 4: the amplification efficiency before optimization of Q-RP-F + Q-RP-R;
FIG. 5: the amplification efficiency of the optimized Q-PLP1-LF + Q-PLP1-LR is high;
FIG. 6: Q-PLP1-MF + Q-PLP1-MR optimized amplification efficiency;
FIG. 7: Q-PLP1-RF + Q-PLP1-RR optimized amplification efficiency;
FIG. 8: the amplification efficiency of the optimized Q-RP-F + Q-RP-R is improved;
FIG. 9: the pre-optimization dissolution curve of Q-PLP1-LF + Q-PLP 1-LR;
FIG. 10: Q-PLP1-MF + Q-PLP1-MR pre-optimization dissolution profile;
FIG. 11: the pre-optimized dissolution profile of Q-PLP1-RF + Q-PLP 1-RR;
FIG. 12: the dissolution curve before optimization of Q-RP-F + Q-RP-R;
FIG. 13: the optimized dissolution curve of PLP1-LF + Q-PLP 1-LR;
FIG. 14: the dissolution curve of Q-PLP1-MF + Q-PLP1-MR after optimization;
FIG. 15: the optimized dissolution curve of Q-PLP1-RF + Q-PLP 1-RR;
FIG. 16: the dissolution curve of the optimized Q-RP-F + Q-RP-R.
Detailed Description
1. Primer testing
1) Linear DNA preparation (table 1): the standard Human genetic DNA (253ng/ul) was diluted in a gradient, 13ul was added to 37ul ddH2O, vortex, and micro-separate to a concentration of 66 ng/uL.
Then 10 fold gradient dilution, 20ul was added to 180ul ddH2In O, the next gradient dilution can be carried out after full vortex mixing is needed each time.
TABLE 1
Figure BDA0002832454290000041
2) Experiment system (Table 2)
TABLE 2
Figure BDA0002832454290000042
3) Amplification procedure (Table 3)
TABLE 3
Figure BDA0002832454290000043
4) Analysis of results
ABI7500 settings:
the expert Prop selects quantification-Relative Standard Curve and SYBR Green Reagents.
The results are as follows:
primer OTC-L: the amplification efficiency of the primer is 92.6 percent, and the peak of the dissolution curve is single;
primer OTC-M: the amplification efficiency of the primer is 99 percent, and the peak of the dissolution curve is single;
primer OTC-R: the amplification efficiency of the primer is 93.1 percent, and the peak of a dissolution curve is single;
primer RP: the amplification efficiency of the primer is 94.5 percent, and the peak of the dissolution curve is single;
the amplification efficiency of the primers is as follows: the PCR manual stipulates that similar relative quantitative calculation can be carried out under the condition that the difference of PCR amplification efficiency of two pairs of primers of the target gene and the reference gene RP is not more than 10%. For this reason we stipulate that primers with E values between 90 and 110% pass. As shown in FIGS. 1 to 8, the amplification efficiencies before and after the optimization of the primers are out of the range of 90% to 110%, and the amplification efficiency is poor, while the amplification efficiency after the optimization is close to 100%, and the amplification efficiency is high.
Primers before optimization were as follows:
Q-PLP1-LF：GTCACATACACCCTGTCTTC(SEQ ID NO.9)
Q-PLP1-LR：CAGAGCGAGCACCTTAACAAGGC(SEQ ID NO.10)
Q-PLP1-MF：GGTTTCACCACTGTTCAATAC(SEQ ID NO.11)
Q-PLP1-MR：CCATCTCTAATTATCCTGG(SEQ ID NO.12)
Q-PLP1-RF：GGATTTGAGGAGGGAGTG(SEQ ID NO.13)
Q-PLP1-RR：GACGGCAAAGTTGTAAGTGG(SEQ ID NO.14)。
the internal reference primers before optimization are as follows:
Q-RP-F：AGATTTGGACCTGCGAGCG(SEQ ID NO.15)
Q-RP-R：GAGCGGCTGTCTCCACAAGT(SEQ ID NO.16)。
the optimized primers and the internal reference primers are the primers shown in SEQ ID NO.1 to SEQ ID NO. 8.
Dissolution curve: because SYBR Green dye can not only be specifically combined with a target gene, specific amplification of a primer is required to be ensured, melting curve analysis can be carried out, and a uniform melting peak is qualified. If eliminated PLP1.W2R, non-specific amplification will result in large errors in copy number calculations (non-single dissolution curve peaks). As shown in FIGS. 9-16, the dissolution curve before and after primer optimization shows that the dissolution curve has a single peak and poor effect due to non-specific amplification of primers, while the dissolution curve has a single peak and good effect due to specific amplification of primers.
2. Clinical sample testing
The clinical detection sample is a second-generation sequencing Nextseq 550 platform detection sample, and the result indicates that the sequencing depth of the clinical detection sample in the region of chrX:103,776,996-103,790,598 is lower than half of the adjacent two exon regions, and the IGV result of the clinical detection sample considering the possibility of heterozygous deletion is as follows: the sequencing depth of the region of the chrX 103,776, 996-.
Result verification
1) A reagent such as 2 × AceQ SYBR qPCR Master Mix is diluted to 5 μ M and thawed at normal temperature, and an EP tube, a tip, and a sample application gun are prepared.
2) The reagents and primers were shaken slightly and then centrifuged instantaneously. The EP tube was labeled according to the kind of primer.
3) The system was prepared according to the test items (table 4):
TABLE 4
Figure BDA0002832454290000061
4) Reagent and sample set-up
The prepared reagents were added to a 96-well optical PCR plate and ready for loading (FIG. 1). Adding the same sample into a group of 12 holes; wherein, one part is a target gene primer system, the other part is an internal reference gene RP primer system, and the three parts are all provided with three compound holes. A normal human sample STD and an NTC must be included in each primer test. Sample1, Sample 2, and Sample 3 in this experiment correspond to the second generation sequencing Sample and its parents, respectively.
5) The sample DNA concentration was determined and diluted to 5ng/ul and 2ul of the diluted sample was pipetted into the corresponding wells. After covering and sealing the membrane, the membrane is centrifuged for a short time and prepared for ABI7500 amplification.
6) And (4) operating the computer ABI7500 and setting software.
(1)Experiment properties：
The type of experiment: quantitation-comparative CT (Delta CT)
Reagent type: SYBR @ Green Regents
Other parameters are defaulted.
(2)Plate setup：
Define target, namely naming a target gene and an internal reference gene RP respectively;
a Define sample is named;
selecting the position of the named gene and sample;
selecting Reference sample as STD;
selecting RP by endogenesis control;
select the ROX for passive reconfiguration.
Other parameters are defaulted.
(3) Run method with an experimental system of 20ul (Table 5);
TABLE 5
Figure BDA0002832454290000071
7) Analysis of results
By deriving raw CT data (table 6):
TABLE 6
SampleP SampleF SampleM STD
OTC-L 30.96 25.14 26.91 23.79
OTC-M 30.32 24.44 24.89 23.52
OTC-R 30.84 24.62 24.21 23.16
RP 22.99 23.89 23.49 23.42
Δ Ct ═ Ct (target gene) -Ct (reference gene)
Δ Δ Ct ═ Δ Ct (sample to be measured) - Δ Ct (std)
Copy number 2^ (2^ -Delta Ct)
The value of 2X (2^ -delta. Ct) of each data was calculated according to the calculation formula (Table 7)
TABLE 7
SampleP SampleF SampleM
OTC-L 0.01 1.23 1.07
OTC-M 0.02 1.25 1.21
OTC-R 0.02 1.20 1.21
Copy number of each sample data (Table 8)
TABLE 8
SampleP SampleF SampleM
OTC-L Zero copy Single copy Single copy
OTC-M Zero copy Single copy Single copy
OTC-R Zero copy Single copy Single copy
The results show that the calculated results of the 3 groups of primers are similar to those of the same sample, and are in line with expectation, and the obtained copy number result is consistent with the second-generation sequencing and shows that the deletion is from the mother. The primer can be used for detecting copy number variation of the region of the PLP1 gene chrX 103,776,996-103, 790-598.
Sequence listing
<110> Changsha gold Domain medical laboratory Co., Ltd
<120> a kit for detecting copy number variation of PLP1 gene
<141> 2020-12-11
<160> 16
<170> SIPOSequenceListing 1.0
<210> 1
<211> 21
<212> DNA
<213> null
<400> 1
ggtcacatac accctgtcaa c 21
<210> 2
<211> 24
<212> DNA
<213> null
<400> 2
ccagagcgag caccttaaca tcgc 24
<210> 3
<211> 24
<212> DNA
<213> null
<400> 3
caaggtttca ccactgttca aatc 24
<210> 4
<211> 22
<212> DNA
<213> null
<400> 4
ccatctctaa ttatcctggg ag 22
<210> 5
<211> 20
<212> DNA
<213> null
<400> 5
gggatttgag gagggagacc 20
<210> 6
<211> 22
<212> DNA
<213> null
<400> 6
ggacggcaaa gttgtaagac gc 22
<210> 7
<211> 22
<212> DNA
<213> null
<400> 7
gcagatttgg acctgcgacg gg 22
<210> 8
<211> 24
<212> DNA
<213> null
<400> 8
gtgagcggct gtctccacaa cacc 24
<210> 9
<211> 20
<212> DNA
<213> null
<400> 9
gtcacataca ccctgtcttc 20
<210> 10
<211> 23
<212> DNA
<213> null
<400> 10
cagagcgagc accttaacaa ggc 23
<210> 11
<211> 21
<212> DNA
<213> null
<400> 11
ggtttcacca ctgttcaata c 21
<210> 12
<211> 19
<212> DNA
<213> null
<400> 12
ccatctctaa ttatcctgg 19
<210> 13
<211> 18
<212> DNA
<213> null
<400> 13
ggatttgagg agggagtg 18
<210> 14
<211> 20
<212> DNA
<213> null
<400> 14
gacggcaaag ttgtaagtgg 20
<210> 15
<211> 19
<212> DNA
<213> null
<400> 15
agatttggac ctgcgagcg 19
<210> 16
<211> 20
<212> DNA
<213> null
<400> 16
gagcggctgt ctccacaagt 20

Claims (3)

1. A kit for detecting copy number variation of PLP1 gene, which is characterized in that the kit contains the following primer pairs:
Q-PLP1-LF：GGTCACATACACCCTGTCAAC
Q-PLP1-LR：CCAGAGCGAGCACCTTAACATCGC
Q-PLP1-MF：CAAGGTTTCACCACTGTTCAAATC
Q-PLP1-MR：CCATCTCTAATTATCCTGGGAG
Q-PLP1-RF：GGGATTTGAGGAGGGAGACC
Q-PLP1-RR：GGACGGCAAAGTTGTAAGACGC。
2. the kit of claim 1, further comprising an internal reference primer pair:
Q-RP-F：GCAGATTTGGACCTGCGACGGG
Q-RP-R：GTGAGCGGCTGTCTCCACAACACC。
3. the kit according to claim 1 or 2, wherein the procedure for amplification using the primer pair of the kit according to claim 1 or 2 is as follows:
①：95℃，5min；
②：95℃，10s；55℃，30s；40Cycles；
③：95℃，15s；55℃，60s；95℃，15s。
CN202011453524.8A 2020-12-11 2020-12-11 Kit for detecting copy number variation of PLP1 gene Pending CN112481371A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011453524.8A CN112481371A (en) 2020-12-11 2020-12-11 Kit for detecting copy number variation of PLP1 gene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011453524.8A CN112481371A (en) 2020-12-11 2020-12-11 Kit for detecting copy number variation of PLP1 gene

Publications (1)

Publication Number Publication Date
CN112481371A true CN112481371A (en) 2021-03-12

Family

ID=74916188

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011453524.8A Pending CN112481371A (en) 2020-12-11 2020-12-11 Kit for detecting copy number variation of PLP1 gene

Country Status (1)

Country Link
CN (1) CN112481371A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114231610A (en) * 2021-11-25 2022-03-25 长沙金域医学检验实验室有限公司 Kit for detecting copy number variation of SCN1A gene

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120322058A1 (en) * 2011-02-09 2012-12-20 Bio-Rad Laboratories Analysis of nucleic acids
CN110305948A (en) * 2018-03-20 2019-10-08 中国科学院上海生命科学研究院 A kind of reagent and method detecting self-closing disease related gene UBE3A copy number
CN111254500A (en) * 2012-12-10 2020-06-09 分析生物科学有限公司 Method for targeted genomic analysis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120322058A1 (en) * 2011-02-09 2012-12-20 Bio-Rad Laboratories Analysis of nucleic acids
CN111254500A (en) * 2012-12-10 2020-06-09 分析生物科学有限公司 Method for targeted genomic analysis
CN110305948A (en) * 2018-03-20 2019-10-08 中国科学院上海生命科学研究院 A kind of reagent and method detecting self-closing disease related gene UBE3A copy number

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STUART CANTSILIERIS 等: "Molecular methods for genotyping complex copy number polymorphisms", GENOMICS, vol. 101, no. 2, pages 86 - 93, XP028577382, DOI: 10.1016/j.ygeno.2012.10.004 *
TAICHI IMAIZUMI 等: "Advantages of ddPCR in detection of PLP1 duplications", INTRACTABLE & RARE DISEASES RESEARCH, vol. 8, no. 3, pages 198 - 202 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114231610A (en) * 2021-11-25 2022-03-25 长沙金域医学检验实验室有限公司 Kit for detecting copy number variation of SCN1A gene

Similar Documents

Publication Publication Date Title
CN115678976B (en) Kit for simultaneously detecting 26 deafness susceptibility gene mutation sites based on time-of-flight mass spectrum and application thereof
CN114085903B (en) Primer pair probe combination product for detecting mitochondria 3243A &amp; gtG mutation, kit and detection method thereof
CN106755395B (en) Mutation site of XI type osteogenesis imperfecta pathogenic gene FKBP10 and application thereof
Minucci et al. Competitive PCR-high resolution melting analysis (C-PCR-HRMA) for large genomic rearrangements (LGRs) detection: a new approach to assess quantitative status of BRCA1 gene in a reference laboratory
CN110747269A (en) Granular cell biomarker for PCOS diagnosis, screening method thereof and diagnostic kit
CN106987637B (en) Amplification primer and kit for detecting familial retinitis pigmentosa disease-causing gene mutation and application
CN116103417A (en) Real-time fluorescent PCR specific primer and probe combination for helicobacter pylori vacA genotyping
CN110846408A (en) Primer combination for detecting TTN gene mutation and application thereof
CN113136418B (en) Composition of primer and probe for detecting microdeletion of Y chromosome, detection method and kit for non-diagnosis purpose
CN112481371A (en) Kit for detecting copy number variation of PLP1 gene
CN112442530B (en) Method for detecting CAH related true and false gene
CN112522386A (en) Kit for detecting copy number variation of MECP2 gene
CN112522385A (en) Kit for detecting DNM2 gene copy number variation
CN112322726A (en) Kit for detecting copy number variation of OTC (over-the-counter) gene
CN113930485B (en) Reagent for detecting gene copy number variation and application thereof
CN115992212A (en) UBE3A mutant protein, UBE3A gene mutant, amplification primer, detection reagent and application
CN116004775A (en) Primer probe composition, kit and method for quantifying copy number of human motor neurons
CN114958988A (en) Multiple nucleic acid detection method and kit based on probe melting curve analysis
TWI674320B (en) Method and kit for making prognosis on gitelman&#39;s syndrome
CN111172248A (en) General kit for verifying copy number variation based on fragment analysis technology
CN114231610A (en) Kit for detecting copy number variation of SCN1A gene
CN107267645B (en) Primer pair, probe and kit for detecting MTHFR gene polymorphism
CN112301120A (en) Probe, primer and kit for detecting ADRB1 gene polymorphism
KR101100323B1 (en) Polynucleotides derived from PCMT1 gene comprising single nucleotide polymorphism, microarrays and diagnostic kits comprising the same, and analytic methods using the same
CN117512085B (en) Primer group and kit for detecting HLA-DPB1 genotyping

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210312

RJ01 Rejection of invention patent application after publication